Please reload

Follow Us

May 9, 2017

Three weeks after treatment with oral miltefosine offers promising hope for patients with AK.  Miltefosine is not yet approved for AK but has received orphan drug designation.

Please reload

  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

October 6, 2017

Please reload

Recent Posts
Search By Tags
Featured Posts

CDC Video showing N.Fowleri

July 21, 2017

1/4
Please reload

Archive
Please reload

 Impavido® (miltefosine) is an FDA-approved treatment for cutaneous,  mucosal and visceral leishmaniasis in patients 12 years of age and older. PLEASE SEE FULL PRESCRIBING INFO